Cannabidiol as potential treatment in refractory pediatric epilepsy

Maria Chiara Paolino, Alessandro Ferretti, Laura Papetti, Maria Pia Villa, Pasquale Parisi

Research output: Contribution to journalArticle

Abstract

In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalExpert Review of Neurotherapeutics
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2 2016

Fingerprint

Cannabidiol
Epilepsy
Pediatrics
Safety
Cannabis
Anticonvulsants
Therapeutics
Animal Models
Pharmacokinetics
Placebos
Pharmaceutical Preparations

Keywords

  • cannabidiol
  • Cannabis
  • CBD
  • epilepsy
  • refractory epilepsy in children

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Cannabidiol as potential treatment in refractory pediatric epilepsy. / Paolino, Maria Chiara; Ferretti, Alessandro; Papetti, Laura; Villa, Maria Pia; Parisi, Pasquale.

In: Expert Review of Neurotherapeutics, Vol. 16, No. 1, 02.01.2016, p. 17-21.

Research output: Contribution to journalArticle

Paolino, Maria Chiara ; Ferretti, Alessandro ; Papetti, Laura ; Villa, Maria Pia ; Parisi, Pasquale. / Cannabidiol as potential treatment in refractory pediatric epilepsy. In: Expert Review of Neurotherapeutics. 2016 ; Vol. 16, No. 1. pp. 17-21.
@article{dd13c1fd3cf946f1b289a4f9518588cc,
title = "Cannabidiol as potential treatment in refractory pediatric epilepsy",
abstract = "In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.",
keywords = "cannabidiol, Cannabis, CBD, epilepsy, refractory epilepsy in children",
author = "Paolino, {Maria Chiara} and Alessandro Ferretti and Laura Papetti and Villa, {Maria Pia} and Pasquale Parisi",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/14737175.2016.1121098",
language = "English",
volume = "16",
pages = "17--21",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Cannabidiol as potential treatment in refractory pediatric epilepsy

AU - Paolino, Maria Chiara

AU - Ferretti, Alessandro

AU - Papetti, Laura

AU - Villa, Maria Pia

AU - Parisi, Pasquale

PY - 2016/1/2

Y1 - 2016/1/2

N2 - In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

AB - In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

KW - cannabidiol

KW - Cannabis

KW - CBD

KW - epilepsy

KW - refractory epilepsy in children

UR - http://www.scopus.com/inward/record.url?scp=84955330429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955330429&partnerID=8YFLogxK

U2 - 10.1586/14737175.2016.1121098

DO - 10.1586/14737175.2016.1121098

M3 - Article

AN - SCOPUS:84955330429

VL - 16

SP - 17

EP - 21

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -